AMIDE AND UREA DERIVATIVES AS 5HT1D RECEPTOR ANTAGONISTS
申请人:SMITHKLINE BEECHAM PLC
公开号:EP0714389A1
公开(公告)日:1996-06-05
US5905080A
申请人:——
公开号:US5905080A
公开(公告)日:1999-05-18
[EN] AMIDE AND UREA DERIVATIVES AS 5HT1D RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'AMIDE ET D'UREE EN TANT QU'ANTAGONISTES DU RECEPTEUR 5HT1D
申请人:SMITHKLINE BEECHAM PLC
公开号:WO1995006044A1
公开(公告)日:1995-03-02
(EN) Novel amide and urea derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments are disclosed.(FR) L'invention concerne des nouveaux dérivés d'amide et d'urée, leurs procédés de préparation, les compositions pharmaceutiques les contenant et leur utilisation comme médicaments.
[EN] HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER<br/>[FR] INHIBITEURS DE HTR1D ET LEURS UTILISATIONS DANS LE TRAITEMENT DU CANCER
申请人:INST CURIE
公开号:WO2020183011A1
公开(公告)日:2020-09-17
The present invention deals with a 5 -hydroxytryptamine receptor 1D (5-HTR1D) inhibitor and with a combination of a 5-HTR1D inhibitor and at least one inhibitor of 5 -hydroxytryptamine receptor 1B (5-HTR1B) for use in the prevention and/or treatment of cancer in a subject in need thereof. According to the invention the cancer may be selected from the group comprising breast cancer, liver cancer, lung cancer, brain cancer, mesothelioma, head and neck squamous cell carcinoma, kidney cancer, gastric cancer and cervix cancer.
Amide and urea derivatives as 5HT1D receptor antagonists
申请人:SmithKline Beecham, p.l.c.
公开号:US05905080A1
公开(公告)日:1999-05-18
Novel amide and urea derivatives, processes for their preparation, pharmaceutical compositions containing hem and their use as medicaments are disclosed.